Ventripoint Diagnostics Ltd. (TSXV:VPT; OTC:VPTDF) announced it will exhibit at the 59th Annual Meeting of the Association for European Paediatric and Congenital Cardiology (AEPC), scheduled for May 12-16, 2026 in Padua, Italy. The event, hosted by the University of Padova, is expected to draw over 1,000 specialists from 32 European countries and beyond, making it the largest gathering of congenital cardiology professionals globally.
The company will showcase its VMS+™ platform alongside European distributor AngioPro, with a focus on supporting longitudinal assessment of cardiac function in congenital heart disease (CHD) patients. This approach aligns with the 2020 ESC Guidelines for Adult Congenital Heart Disease, co-endorsed by AEPC, which emphasize echocardiography as the primary modality for serial ventricular function monitoring in CHD (Baumgartner et al., European Heart Journal, 2021; doi:10.1093/eurheartj/ehaa554).
VMS+™ 4.0, the latest iteration, is designed to streamline clinical workflows, reduce assessment time, and deliver volumetric cardiac measurements equivalent to MRI at the point of care. This capability enables clinicians to obtain detailed insights from a patient's first echocardiogram, supporting earlier and more informed clinical decisions throughout the patient's lifetime.
“AEPC represents the heart of the European congenital cardiology community, and we are proud to be part of it,” said Hugh MacNaught, President and CEO of Ventripoint. “VMS+™ delivers fast, affordable, and accessible volumetric cardiac assessments with accuracy comparable to MRI – giving clinicians the confidence they need to manage their patients at every stage of life.”
Ventripoint’s priority for 2026 is accelerating the integration of VMS+™ into routine practice and building better care pathways for CHD patients. The company’s KBR technology, developed over more than a decade, powers the VMS+™ product family, which is compatible with ultrasound systems from all major vendors and holds regulatory approvals in the U.S., Europe, and Canada.
The AEPC meeting this year features a scientific program centred on advanced cardiovascular imaging and artificial intelligence, areas where Ventripoint is driving clinical progress. By exhibiting at the event, the company aims to engage with clinicians and existing customers, highlighting the potential of VMS+™ to transform CHD management.
For further information, visit the company’s profile on SEDAR at www.sedar.com.
